Drug Trial Radar · NCT05224102
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
218
Planned (sponsor's estimate)
Start
Feb 28, 2022
Primary completion
Jan 26, 2027
Study completion Jan 26, 2027
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Feb 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.
Conditions
- Diabetic Macular Edema
Interventions
FaricimabDrug
Participants will receive 6-milligram (mg) faricimab intravitreal (IVT) injections, as described in the study arm descriptions for each study phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Main Phase: Change in Best Corrected Visual Acuity (BCVA) from Baseline at Week 56, as Measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at a Starting Distance of 4 MetersTime frame: From Baseline to Week 56
- Long-Term Extension Phase: Incidence and Severity of Ocular Adverse EventsTime frame: From Day 1 until end of long-term extension (up to 100 weeks)
- Long-Term Extension Phase: Incidence and Severity of Non-Ocular Adverse EventsTime frame: From Day 1 until end of long-term extension (up to 100 weeks)
Locations
43 sites in 4 countries. Site status is shown where the registry gives one.
Barnet Dulaney Perkins Eye Center
Phoenix, Arizona
Win Retina
Arcadia, California
Retinal Diagnostic Center
Campbell, California
Retina Consultants of Orange County
Fullerton, California
Kaiser Permanente Southern California
Los Angeles, California
Retinal Consultants Medical Group
Sacramento, California
Southwest Retina Consultants
Durango, Colorado
Emerson Clinical Research Institute LLC
Washington D.C., District of Columbia
Blue Ocean Clinical Research
Clearwater, Florida
Retina Macula Specialists of Miami - LeJeune Road Office
Miami, Florida
Florida Retina Institute
Orlando, Florida
Fort Lauderdale Eye Institute
Plantation, Florida
University Retina and Macula Associates, PC
Oak Forest, Illinois
Wilmer Eye Institute Johns Hopkins University
Baltimore, Maryland
Md Medical Research
Oxon Hill, Maryland
Retina Associates of Michigan
Grand Blanc, Michigan
Retina Consultants of Nevada
Henderson, Nevada
Sierra Eye Associates
Reno, Nevada
The Retina Center of New Jersey
Bloomfield, New Jersey
NJ Retina - Teaneck
Teaneck, New Jersey
Piedmont Retina Specialists
Winston-Salem, North Carolina
Retina Associates of Cleveland, INC
Beachwood, Ohio
Scheie Eye Institute
Philadelphia, Pennsylvania
Wills Eye Hospital
Philadelphia, Pennsylvania
Black Hills Eye Institute
Rapid City, South Dakota
Charles Retina Institute
Memphis, Tennessee
Austin Clinical Research LLC
Austin, Texas
Retina & Vitreous of Texas
Bellaire, Texas
Retina Consultants of Texas Westover Hills Retina Center
San Antonio, Texas
Retina Center of Texas
Southlake, Texas
Strategic Clinical Research Group, LLC
Willow Park, Texas
Piedmont Eye Center
Lynchburg, Virginia
Wagner Kapoor Institute
Norfolk, Virginia
Post Graduate Institute of Medical Education and Research (PGIMER)
Chandigarh, India
MM Joshi Eye Institute
Hubli, Karnataka, India
PBMA'S H. V. Desai Eye Hospital
Pune, Maharashtra, India
M & J Western Regional Institute of Ophthalmology
Ahmedabad, Rajasthan, India
Sankara Nethralaya
Chennai, Tamil Nadu, India
Aravind Eye Hospital
Madurai, Tamil Nadu, India
Regional Institute of Ophthalmology
Kolkata, West Bengal, India
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.